As filed with the Securities and Exchange Commission on March 16, 2020

Registration No. 333-            

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Aerpio Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   61-1547850

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification Number)

Aerpio Pharmaceuticals, Inc.

9987 Carver Road, Suite 420

Cincinnati, OH

  45242
(Address of Principal Executive Offices)   (Zip Code)

 

 

2017 Stock Option and Incentive Plan

Amended and Restated 2017 Employee Stock Purchase Plan

(Full Title of the Plan)

Joseph Gardner

President

Aerpio Pharmaceuticals, Inc.

9987 Carver Road, Suite 420

Cincinnati, OH 45242

(Name and Address of Agent for Service)

(513) 985-1920

(Telephone Number, Including Area Code, of Agent For Service)

 

 

Copies to:

Kingsley L. Taft, Esq.

Danielle M. Lauzon, Esq.

James Xu, Esq.

Goodwin Procter LLP

100 Northern Avenue

Boston, Massachusetts 02210

(617) 570-1000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
    

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☒

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of Securities

To Be Registered

 

Amount

To Be

Registered (1)

 

Proposed

Maximum

Offering Price

Per Share

 

Proposed

Maximum

Aggregate

Offering Price

 

Amount of

Registration Fee (6)

Common Stock, par value $0.0001 per share

  1,623,520 shares(2)   $0.60(3)   $974,112   $126.44

Common Stock, par value $0.0001 per share

  350,000 shares(4)   $0.51(5)   $178,500   $23.17

Total

  1,973,520 shares       $1,152,612   $149.61

 

 

(1)

In accordance with Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall be deemed to cover any additional shares of Common Stock that may become issuable under the Registrant’s 2017 Stock Option and Incentive Plan (the “2017 Plan”) and Amended and Restated 2017 Employee Stock Purchase Plan (the “2017 ESPP”) resulting from stock splits, stock dividends, recapitalizations or similar transactions effected without the receipt of consideration which results in an increase in the number of the Registrant’s outstanding shares of Common Stock.

(2)

Represents an automatic increase of 1,623,520 shares of the Registrant’s Common Stock to the number of shares available for issuance under the 2017 Plan, effective January 1, 2020. Shares available for issuance under the 2017 Plan were previously registered on a registration statement on Form S-8 filed with the Securities and Exchange Commission on August 18, 2017 (Registration No. 333-220057), on April 6, 2018 (Registration No. 333-224189) and on March 7, 2019 (Registration No. 333-230114).

(3)

The price of $0.60 per share, which is the average of the high and low sale prices of the Common Stock of the Registrant as quoted on the Nasdaq Capital Market on March 10, 2020, is set forth solely for purposes of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act and has been used as these shares are without a fixed price.

(4)

Represents an automatic increase of 350,000 shares of the Registrant’s Common Stock to the number of shares available for issuance under the 2017 ESPP, effective January 1, 2020. Shares available for issuance under the 2017 ESPP were previously registered on a registration statement on Form S-8 filed with the Securities and Exchange Commission on August 18, 2017 (Registration No. 333-220057) and on March 7, 2019 (Registration No. 333-230114).

(5)

The price of $0.51 per share, which is 85% of the average of the high and low sale prices of the Common Stock of the Registrant as quoted on the Nasdaq Capital Market on March 10, 2020, is set forth solely for purposes of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act and has been used as these shares are without a fixed price. Pursuant to the 2017 Employee Stock Purchase Plan, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the fair market value of a share of Common Stock on the first trading day of the offering period or on the exercise date, whichever is less.

(6)

Calculated pursuant to Section 6(b) of the Securities Act.

 

 

 


EXPLANATORY NOTE

This Registration Statement on Form S-8 relating to the 2017 Plan and the 2017 ESPP of Aerpio Pharmaceuticals, Inc. (the “Registrant”) registers additional securities of the same class as other securities for which the Registrant’s registration statement filed on Form S-8 (Registration No. 333-220057) on August 18, 2017 on Form S-8 (Registration No. 333-224189) on April 6, 2018 and on Form S-8 (Registration No. 333-230114) on March 7, 2019, are effective. Accordingly, the information contained in the Registrant’s Registration Statement on Form S-8 (SEC File No. 333-220057) is hereby incorporated by reference pursuant to General Instruction E, except for “Item 8. Exhibits” with respect to which the Exhibit Index is incorporated herein by reference.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8. Exhibits.

 

Exhibit

No.

   Description of Exhibit
  4.1    Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Form 8-K filed with the Securities and Exchange Commission on March 17, 2017, File No. 000-53057)
  4.2    Amended and Restated By-laws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.3 to the Registrant’s Form 8-K filed with the Securities and Exchange Commission on March 17, 2017, File No. 000-53057)
  4.3    Specimen Stock Certificate evidencing shares of common stock (incorporated herein by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-217320) filed on April 14, 2017)
  4.4    Form of Warrant Agreement (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 000-53057) filed on March 17, 2017)
  5.1*    Opinion of Goodwin Procter LLP
23.1*    Consent of Goodwin Procter LLP (included in Exhibit 5.1)
23.2*    Consent of Ernst & Young LLP
24.1*    Power of Attorney (included as part of the signature page of this Registration Statement)
99.1    2017 Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 000-53057) filed on March 17, 2017)
99.2    Amended and Restated 2017 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 000-53057) filed on December 18, 2017)


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cincinnati, State of Ohio, on March 16, 2020.

 

AERPIO PHARMACEUTICALS, INC.
By:  

/s/ Joseph Gardner, Ph.D.

 

Joseph Gardner, Ph.D.

President and Principal Executive Officer

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Aerpio Pharmaceuticals, Inc. (the “Company”), hereby severally constitute and appoint Joseph Gardner and Regina Marek, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments (including post-effective amendments) to this Registration Statement, and all other documents in connection therewith to be filed with the Securities and Exchange Commission, and generally to do all things in our names and on our behalf in such capacities to enable the Company to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature    Title(s)    Date

/s/ Joseph Gardner, Ph.D.

Joseph Gardner, Ph.D.

   President, Founder and Director (Principal Executive Officer)    March 16, 2020

/s/ Regina Marek

Regina Marek

  

Vice President, Finance (Principal Financial and

Accounting Officer)

   March 16, 2020

/s/ Muneer A. Satter

Muneer A. Satter

   Chairman of the Board of Directors    March 16, 2020

/s/ Chau Khuong

Chau Khuong

   Director    March 16, 2020

/s/ Cheryl Cohen

Cheryl Cohen

   Director    March 16, 2020

/s/ Anupam Dalal, M.D.

Anupam Dalal, M.D.

   Director    March 16, 2020

/s/ Caley Castelein, M.D.

Caley Castelein, M.D.

   Director    March 16, 2020

/s/ Pravin Dugel, M.D.

Pravin Dugel, M.D.

   Director    March 16, 2020

/s/ Steven Prelack

Steven Prelack

   Director    March 16, 2020
Aerpio Pharmaceuticals (NASDAQ:ARPO)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Aerpio Pharmaceuticals Charts.
Aerpio Pharmaceuticals (NASDAQ:ARPO)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Aerpio Pharmaceuticals Charts.